Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients

Ageno W. Gallus A. S. Wittkowsky A. Crowther M. Hylek E. M. Palareti G. , & American College of Chest Physicians. (2012). Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e44S–e88S.

Akl E. A. Kahale L. Barba M. Neumann I. Labedi N. Terrenato I. … Schunemann H. (2014). Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews, 7, CD006650. doi:10.1002/14651858.CD006650.pub4

Anguita Sánchez M. Bertomeu Martínez V. Cequier Fillat A. (2015). Quality of vitamin K antagonist anticoagulation in Spain: Prevalence of poor control and associated factors. Revista Española de Cardiología (English Version), 68, 761–768.

Ansell J. Hirsh J. Hylek E. Jacobson A. Crowther M. Palareti G. (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest, 133, 160S–198S.

Ansell J. Hollowell J. Pengo V. Martinez-Brotons F. Caro J. Drouet L. (2007). Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The international study of anticoagulation management (ISAM). Journal of Thrombosis and Thrombolysis, 23, 83–91.

Apostolakis S. Sullivan R. M. Olshansky B. Lip G. Y. (2013). Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT(2)R(2) score. Chest, 144, 1555–1563.

Asinger R. W. Shroff G. R. (2015). Atrial fibrillation and renal function: How high is the price of anticoagulation? Journal of the American College of Cardiology, 65, 2494–2495.

Bauersachs R. M. Lensing A. W. Prins M. H. Kubitza D. Pap A. F. Decousus H. … Prandoni P. (2014). Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thrombosis Journal, 12, 25.

Becattini C. Vedovati M. C. Agnelli G. (2012). Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thrombosis Research, 129, 392–400.

Bezemer I. D. Roemer W. H. Penning-van Beest F. J. van Eekelen E. Kramer M. H. (2013). INR control calculation: Comparison of Dutch and international methods. Netherlands Journal of Medicine, 71, 194–198.

Burgazli K. M. Atmaca N. Mericliler M. Parahuleva M. Erdogan A. Daebritz S. H. (2013). Deep vein thrombosis and novel oral anticoagulants: A clinical review. European Review for Medical and Pharmacological Sciences, 17, 3123–3131.

Cabrera Rayo A. Nellen Hummel H. (2007). Epidemiología de la enfermedad tromboembólica venosa. Gaceta Médica de México, 143, 3–5.

Cai J. Preblick R. Zhang Q. Kwong W. J. (2014). Utilization of parenteral anticoagulants and warfarin: Impact on the risk of venous thromboembolism recurrence in the outpatient setting. American Health & Drug Benefits, 7, 444–451.

Capodanno D. Angiolillo D. J. (2012). Antithrombotic therapy in patients with chronic kidney disease. Circulation, 125, 2649–2661.

Carrier M. Kimpton M. Wells P. S. Langlois N. Kherani S. Le Gal G. (2014). A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants. Blood Coagulation & Fibrinolysis, 25, 812–815.

Clarkesmith D. E. Pattison H. M. Lip G. Y. Lane D. A. (2013). Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. PLoS One, 8, e74037.

Corral J. González-Conejero R. Ordóñez A. Martínez-Martínez I. (2008). Trombofilia. Medicine, 10, 1475–1482.

Costa G. L. Lamego R. M. Colosimo E. A. Valacio R. A. Vieira Moreira M. D. C. (2012). Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: A prospective, long-term, single-center, observational study. Clinical Therapeutics, 34, 1511–1520.

Engbers M. J. Blom J. W. Cushman M. Rosendaal F. R. van Hylckama Vlieg A. (2014). The contribution of immobility risk factors to the incidence of venous thrombosis in an older population. Journal of Thrombosis and Haemostasis, 12, 290–296.

Erkens P. M. ten Cate H. Buller H. R. Prins M. H. (2012). Benchmark for time in therapeutic range in venous thromboembolism: A systematic review and meta-analysis. PLoS One, 7, e42269.

Francavilla C. L. (2008). Registered nurse-managed anticoagulation clinic: Improving patient outcomes. Nursing Economics, 26, 130–132.

Gallego P. Roldán V. Marín F. Gálvez J. Valdés M. Vicente V. Lip G. Y. (2014). SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. American Journal of Medicine, 127, 1083–1088.

Gerotziafas G. T. Mahe I. Elalamy I. (2014). New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Journal of Therapeutics and Clinical Risk Management, 10, 423–436.

Go A. S. Mozaffarian D. Roger V. L. Benjamin E. J. Berry J. D. Borden W. B. … Turner M. B. (2013). Executive summary: Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation, 127, 143–152.

Harel Z. Sood M. M. Perl J. (2015). Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 24, 183–192.

Hefter G. B. Stack J. (2011). Development of a dosing algorithm in a nurse-managed outpatient anticoagulation clinic. Journal of the American Academy of Nurse Practitioners, 23, 546–551.

ISTH Steering Committee for World Thrombosis Day. (2014). Thrombosis: A major contributor to global disease burden. Thrombosis Research, 134, 931–938.

Jun M. James M. T. Manns B. J. Quinn R. R. Ravani P. Tonelli M. … Hemmelgarn B. R. (2015). The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: Population based observational study. British Medical Journal, 350, h246.

Kearon C. Akl E. A. Comerota A. J. Prandoni P. Bounameaux H. Goldhaber S. Z. … Kahn S. R. (2012). Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e419S–494S.

Le Gal G. Righini M. (2015). Controversies in the diagnosis of venous thromboembolism. Journal of Thrombosis and Haemostasis, 13, S259–S265.

Lega J. C. Bertoletti L. Gremillet C. Boissier C. Mismetti P. Laporte S. (2014). Consistency of safety profile of new oral anticoagulants in patients with renal failure. Journal of Thrombosis and Haemostasis, 12, 337–343.

Lip G. Y. Haguenoer K. Saint-Etienne C. Fauchier L. (2014). Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest, 146, 719–726.

Løkkegaard T. Pedersen T. H. Lind B. Siersma V. Waldorff F. B. (2015). Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing. Danish Medical Journal, 62, A5010.

Lozano R. Naghavi M. Foreman K. Lim S. Shibuya K. Aboyans V. … Memish Z. A. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2095–2128.

Mearns E. S. Kohn C. G. Song J. S. Hawthorne J. Meng J. White C. M. … Coleman C. I. (2014). Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thrombosis Research, 134, 310–319.

Melamed O. C. Horowitz G. Elhayany A. Vinker S. (2011). Quality of anticoagulation control among patients with atrial fibrillation. American Journal of Managed Care, 17, 232–237.

Ministerio de Sanidad, Servicios Sociales e Igualdad. (2013). Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales (NACO) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. Informe de posicionamiento terapéutico UT/V4/23122013. Retrieved November 22, 2015, from http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-orales.pdf

Mueller S. Pfannkuche M. Breithardt G. Bauersachs R. Maywald U. Kohlmann T. Wilke T. (2014). The quality of oral anticoagulation in general practice in patients with atrial fibrillation. European Journal of Internal Medicine, 25, 247–254.

Nakashima M. O. Rogers H. J. (2014). Hypercoagulable states: An algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Research, 49, 85–94.

National Institute for Health and Care Excellence. (2014). Atrial fibrillation: The management of atrial fibrillation. London, England: National Clinical Guideline Centre.

National Kidney Foundation. (2002). K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. American Journal of Kidney Diseases, 39, S1–S266.

Nelson W. W. Choi J. C. Vanderpoel J. Damaraju C. V. Wildgoose P. Fields L. E. Schein J. R. (2013). Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. American Journal of Cardiology, 112, 509–512.

Olie V. Zhu T. Martinez I. Scarabin P. Y. Emmerich J. (2012). Sex-specific risk factors for recurrent venous thromboembolism. Thrombosis Research, 130, 16–20.

Oterhals K. Deaton C. De Geest S. Jaarsma T. Lenzen M. Moons P. … Norekval T. M. (2014). European cardiac nurses’ current practice and knowledge on anticoagulation therapy. European Journal of Cardiovascular Nursing, 13, 261–269.

Palareti G. Legnani C. Cosmi B. Guazzaloca G. Cini M. Mattarozzi S. (2005). Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. Journal of Thrombosis and Haemostasis, 3, 955–961.

Pattacini C. Manotti C. Pini M. Quintavalla R. Dettori A. G. (1994). A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thrombosis and Haemostasis, 71, 188–191.

Roldán V. Cancio S. Gálvez J. Valdés M. Vicente V. Marín F. Lip G. Y. (2015). The SAMe-TTR score predicts poor anticoagulation in atrial fibrillation patients initiating vitamin K antagonists: A prospective “real world” inception cohort study. American Journal of Medicine, 128, 1237–1243.

Roldán V. Marín F. (2015). The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thrombosis and Haemostasis, 113, 671–673.

Rose A. J. Hylek E. M. Ozonoff A. Ash A. S. Reisman J. I. Berlowitz D. R. (2010). Patient characteristics associated with oral anticoagulation control: Results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). Journal of Thrombosis and Haemostasis, 8, 2182–2191.

Rosendaal F. R. Cannegieter S. C. van der Meer F. J. Briet E. (1993). A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and Haemostasis, 69, 236–239.

Ruff C. T. Giugliano R. P. Braunwald E. Hoffman E. B. Deenadayalu N. Ezekowitz M. D. … Antman E. M. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet, 383, 955–962.

Ruiz-Ortiz M. Bertomeu V. Cequier A. Marin F. Anguita M. (2015). Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thrombosis and Haemostasis, 114, 695–701.

Sawicka-Powierza J. Oltarzewska A. M. Chlabicz S. Rogowska-Szadkowska D. Marcinowicz L. (2009). Educational role of community nurse in care of patients treated with oral anticoagulation therapy. Polski Merkuriusz Lekarski, 26, 636–639.

Schulman S. Zondag M. Linkins L. Pasca S. Cheung Y. W. de Sancho M. … Lee A. (2015). Recurrent venous thromboembolism in anticoagulated patients with cancer: Management and short-term prognosis. Journal of Thrombosis and Haemostasis, 13, 1010–1018.

Tagalakis V. Patenaude V. Kahn S. R. Suissa S. (2013). Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE study cohort. American Journal of Medicine, 126, 832.e813–832.e821.

van der Hulle T. Kooiman J. den Exter P. L. Dekkers O. M. Klok F. A. Huisman M. V. (2014). Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 12, 320–328.

van Walraven C. Jennings A. Oake N. Fergusson D. Forster A. J. (2006). Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest, 129, 1155–1166.

Veeger N. J. Piersma-Wichers M. Tijssen J. G. Hillege H. L. van der Meer J. (2005). Individual time within target range in patients treated with vitamin K antagonists: Main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. British Journal of Haematology, 128, 513–519.

Wells P. S. Forgie M. A. Rodger M. A. (2014). Treatment of venous thromboembolism. Journal of the American Medical Association, 311, 717–728.

Wigle P. Hein B. Bloomfield H. E. Tubb M. Doherty M. (2013). Updated guidelines on outpatient anticoagulation. American Family Physician, 87, 556–566.

Yeh C. Gross P. Weitz J. (2014). Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood, 124, 1020–1028.